BioSpace News Archive

Evotec SE announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

The fourth quarter showed a significant increase in business activity and we returned to organic growth. We thereby achieved a new currency-adjusted sales record for the Group, along with clearly improved earnings.

Calliditas Therapeutics AB announced that the first patient has been dosed in the global open-label extension of the Phase 3 NefIgArd study.

With over 60 million surgeries carried out under anesthesia in Europe and the United States each year, RDS has developed a connected strip that facilitates the monitoring of patients at risk of post-surgical complications.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, announced financial results for its fiscal 2021 third quarter that ended December 31, 2020.

With three additional COVID vaccine candidates close to being submitted for consideration for emergency approval by the FDA, AHF urges the Biden administration to aim high with its vaccine dosing goals—to distribute 5 million vaccine doses daily—for a better shot at achieving herd immunity more quickly

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseases to drive improved patient outcomes and advance value-based care, announced today that it will co-host a Capital Markets Day for Kidney Health with the American Society of Nephrology (ASN) on Thursday, February 11 from 8:00 a.m. — 12:30 p.m. EST. The virtual event will bring

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11 at 1:30 p.m. ET

- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.